NasdaqGS:TLRY

Stock Analysis Report

Executive Summary

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis.


Snowflake Analysis

High growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has Tilray's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TLRY's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

36.3%

TLRY

10.6%

US Pharmaceuticals

5.3%

US Market


1 Year Return

-89.2%

TLRY

-6.9%

US Pharmaceuticals

-10.7%

US Market

Return vs Industry: TLRY underperformed the US Pharmaceuticals industry which returned -6.9% over the past year.

Return vs Market: TLRY underperformed the US Market which returned -10.7% over the past year.


Shareholder returns

TLRYIndustryMarket
7 Day36.3%10.6%5.3%
30 Day-55.2%-4.5%-13.6%
90 Day-58.1%-12.3%-19.8%
1 Year-89.2%-89.2%-4.5%-6.9%-8.9%-10.7%
3 Yearn/a12.9%4.8%15.5%8.0%
5 Yearn/a15.8%3.1%35.2%20.4%

Price Volatility Vs. Market

How volatile is Tilray's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tilray undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TLRY ($6.87) is trading below our estimate of fair value ($89.19)

Significantly Below Fair Value: TLRY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TLRY is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: TLRY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TLRY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TLRY is overvalued based on its PB Ratio (2.5x) compared to the US Pharmaceuticals industry average (2.4x).


Next Steps

Future Growth

How is Tilray forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

82.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TLRY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: TLRY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TLRY's is expected to become profitable in the next 3 years.

Revenue vs Market: TLRY's revenue (31.1% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: TLRY's revenue (31.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TLRY is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Tilray performed over the past 5 years?

-374.2%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: TLRY is currently unprofitable.

Growing Profit Margin: TLRY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if TLRY's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare TLRY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLRY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.2%).


Return on Equity

High ROE: TLRY has a negative Return on Equity (-112.58%), as it is currently unprofitable.


Next Steps

Financial Health

How is Tilray's financial position?


Financial Position Analysis

Short Term Liabilities: TLRY's short term assets ($259.0M) exceed its short term liabilities ($92.4M).

Long Term Liabilities: TLRY's short term assets ($259.0M) do not cover its long term liabilities ($518.6M).


Debt to Equity History and Analysis

Debt Level: TLRY's debt to equity ratio (153.3%) is considered high.

Reducing Debt: Insufficient data to determine if TLRY's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: TLRY has a high level of physical assets or inventory.

Debt Coverage by Assets: TLRY's debt is not covered by short term assets (assets are 0.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TLRY has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TLRY has less than a year of cash runway if free cash flow continues to reduce at historical rates of -94.5% each year


Next Steps

Dividend

What is Tilray's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TLRY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TLRY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TLRY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TLRY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TLRY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Brendan Kennedy (47yo)

2.25s

Tenure

US$31,817,459

Compensation

Mr. Brendan Kennedy serves as President and Chief Executive Officer and Director of Tilray, Inc. since January 2018 and serves as its Chairman of the Board. He serves as the Chief Executive Officer and Dir ...


CEO Compensation Analysis

Compensation vs Market: Brendan's total compensation ($USD31.82M) is above average for companies of similar size in the US market ($USD3.17M).

Compensation vs Earnings: Brendan's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Brendan Kennedy
Chairman2.25yrsUS$31.82m13.7% $104.9m
Edward Pastorius
Chief Revenue Officer2.08yrsUS$2.77m0.16% $1.2m
Michael Kruteck
Chief Financial Officer0.083yrno datano data
Jon Levin
Chief Operating Officer0.25yrno datano data
Dara Redler
General Counsel & Corporate Secretary1.25yrsno datano data
Andrew Pucher
Chief Corporate Development Officer1.08yrsno data0.013% $96.0k
Rita Seguin
Executive Vice President of Human Resources1.25yrsno datano data
Greg Christopher
Executive Vice President of Operations0.25yrno datano data
Sascha Mielcarek
Managing Director of Europe1.17yrsno datano data
Josh Eades
Chief Science Officerno datano datano data

1.2yrs

Average Tenure

47yo

Average Age

Experienced Management: TLRY's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Brendan Kennedy
Chairman2.25yrsUS$31.82m13.7% $104.9m
Praveen Anand
Member of Medical Advisory Boardno datano datano data
Catherine Lord
Member of Medical Advisory Boardno datano datano data
Christine St. Clare
Independent Director1.83yrsUS$298.60k0.010% $77.8k
Abraham Chachoua
Member of Medical Advisory Boardno datano datano data
Michael Auerbach
Director2.17yrsUS$522.26k2.38% $18.2m
Rebekah Dopp
Independent Director1.92yrsUS$295.35k0.010% $78.3k
Maryscott Greenwood
Independent Director1.92yrsUS$297.35k0.013% $100.8k
Orrin Devinsky
Chairman of Medical Advisory Boardno datano datano data
Elizabeth Hale
Member of Medical Advisory Boardno datano datano data

1.9yrs

Average Tenure

47yo

Average Age

Experienced Board: TLRY's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21%.


Top Shareholders

Company Information

Tilray, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tilray, Inc.
  • Ticker: TLRY
  • Exchange: NasdaqGS
  • Founded: 2018
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$765.791m
  • Shares outstanding: 111.31m
  • Website: https://www.tilray.com

Number of Employees


Location

  • Tilray, Inc.
  • 1100 Maughan Road
  • Nanaimo
  • British Columbia
  • V9X IJ2
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TLRYNasdaqGS (Nasdaq Global Select)YesClass 2 Common StockUSUSDJul 2018
2HQDB (Deutsche Boerse AG)YesClass 2 Common StockDEEURJul 2018
2HQSWX (SIX Swiss Exchange)YesClass 2 Common StockCHCHFJul 2018
0Z6YLSE (London Stock Exchange)YesClass 2 Common StockGBUSDJul 2018
2HQXTRA (XETRA Trading Platform)YesClass 2 Common StockDEEURJul 2018

Biography

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, pharmacies, governments, and hospitals; and for researchers for commercial purposes, and compassionate access and clinical research applications. It operates in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, the United Kingdom, the United States, and South Africa. The company was incorporated in 2018 and is headquartered in Nanaimo, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/01 05:12
End of Day Share Price2020/03/31 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.